Face-Off: Award Presentations and Event Conclusion
Judy concludes the event and presents the awards.
Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC
A debate presented on liquid biopsy versus tissue biopsy to determine front line therapy in metastatic NSCLC.
Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC
Dr. Florez leads the discussion on the association between Medicaid insurance, biomarker testing, and the outcomes in patients with advanced NSCLC.
Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study
Dr. Herbst discusses the CHRYSALIS Phase 1 trial.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial
An overview of results from the phase III randomized ADAURA Trial.
Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial
A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.
KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC
A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study
A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study
Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC
The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.
Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate
Highlight on the debate format, speakers, and direction to support the discussion.
